Behandlung der multiplen sklerose mit glatiramer-azetat: Aktuelles zu wirkungsmechanismen, pharmakokinetik, nebenwirkungsprofil und studiensituation

Translated title of the contribution: Treatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies

T. Ziemssen, O. Neuhaus, C. Farina, H. P. Hartung, R. Hohlfeld

Research output: Contribution to journalArticle

Abstract

Glatiramer acetate (GA, Copaxone®), a standardized mixture of synthetic polypeptides, has now been approved also in Germany for the treatment of relapsing-remitting multiple sclerosis (RR-MS). After it had been shown effective in suppression of experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), it was evaluated in several clinical studies. In these studies, GA could alter the natural history of MS by both reducing the relapse rate and affecting disability. The clinical therapeutic effect of GA was consistent with the effect on magnetic resonance imaging-defined disease activity and burden in a recent multicenter study. As a daily standard dose, 20 mg of GA is injected subcutaneously. The induction of GA-reactive T-helper 2-like regulatory suppressor cells is thought to be the main mechanism of action. The most common adverse effects are mild injection site reactions. A remarkable but rare adverse effect is the only transient immediate post-injection systemic reaction manifested by flushing, chest tightness, palpitations, and dyspnea. Antibodies to GA which are induced during GA treatment do not interfere with its clinical effects.

Translated title of the contributionTreatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies
Original languageGerman
Pages (from-to)321-331
Number of pages11
JournalNervenarzt
Volume73
Issue number4
DOIs
Publication statusPublished - 2002

Keywords

  • Glatiramer acetate
  • Immunomodulatory therapy
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Treatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies: Aktuelles zu wirkungsmechanismen, pharmakokinetik, nebenwirkungsprofil und studiensituation'. Together they form a unique fingerprint.

  • Cite this